81 results about "Tryptamines" patented technology

This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

A method of purifying 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which comprises dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature, cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT, separating the solid 5-MeO-DMT from the remaining solution and removing solvent from the crystalline 5-MeO-DMT. In the method, the solvent comprises one or more ethers and less than 5 wt % anti-solvent.

This invention belongs to the field of pharmaceutical chemistry, and specifically relates to a compound antifungal cream containing the traditional Chinese medicine ingredient tryptamine ketone and its application. The invention comprises the following components, with the following percentage content: stearic acid 10%~16%, glyceryl monostearate 3%~7%, liquid paraffin 5%~9%, tryptamine 0.1%~0.01%, terbinafine hydrochloride 0.00625%~0.000625%, glycerin 4%, triethanolamine 2%~6%, ethylparaben 0.5%, and the balance being purified water or distilled water. This invention is highly effective, low in toxicity, and exhibits low drug resistance.

The present application belongs to the technical field of pharmaceutical therapy, and particularly relates to an amide-substituted tryptophan ketone derivative, a preparation method and application thereof. The structural formula of the tryptophan ketone derivative is shown in formula (A) or formula (B). In the formula, n=1 or 2, and R is any one of dimethylamine group, diethylamine group, morpholine group, 1-methylpiperazine group, cyclopropylamine group and 4-hydroxypiperidyl group. The compound can selectively inhibit the activity of acetylcholinesterase, and has the potential to develop into a drug for treating Alzheimer's disease due to the abilities of self-aggregation and the like. 1‑42 ​

The invention discloses a method for synthesizing novel alkaloid by enzyme catalysis of tryptamine and alpha-ketoamide substances, and the method comprises the following steps: reacting a compound shown as a formula (A) with a compound shown as a formula (B) in the presence of isoviscin synthetase to obtain alkaloid shown as a formula (C). The method is mild in condition, free of pollution and simple in process route.

The invention discloses an SERS (Surface Enhanced Raman Scattering) aptamer sensor based on a double-layer core-satellite magnetic gold nanostructure and a method for detecting biogenic amine in food by using the SERS aptamer sensor. The Fe3O4 (at) Au MNPs nanoparticles are combined with a nucleic acid aptamer, and a specific magnetic capture probe is obtained; the method comprises the following steps: mixing gold nanoparticle solutions with different particle sizes with 4-MBN, incubating to obtain a'biological silence zone 'SERS tag, and combining the'biological silence zone' SERS tag with pretreated sulfydryl modified c-DNA to obtain a specific SERS signal probe; and oscillating and incubating the specific SERS signal probe solution and the specific magnetic capture probe solution to obtain the SERS aptamer sensor based on the double-layer core-satellite magnetic gold nanostructure. According to the method, a'biological silence zone 'SERS label is combined with a magnetic induction technology, so that the problems of poor anti-interference performance and poor accuracy during detection of trace components in a complex matrix by SERS are solved, and high-efficiency detection of tryptamine in biogenic amine is realized.

The disclosure relates to a compound of formula (1):The disclosure also relates to a compound of formula (Ia):The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

The invention features methods of treating depression in a subject in need thereof by administering to the subject a composition, and kits comprising 5-methoxy-N,N-dimethyltryptamine (5- MeO-DMT) in combination with a composition comprising one or more antidepressants, such as a selective serotonin reuptake inhibitor (SSRI), each in an amount that together are sufficient to treat depression in a patient in need thereof.

The present disclosure relates to solid forms, such as salts, solvates, cocrystals and polymorphs, of Compound 1 as well as cocrystals of Compound 1 HO. Also disclosed are methods of preparing said solid forms, pharmaceutical compositions comprising the solid forms, and methods of treatment using said solid forms.

The present disclosure includes azetidine tryptamines and methods of treating psychiatric disorders with such compounds. Also provided are pharmaceutical compositions comprising azetidine tryptamine.

Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.

The present disclosure includes azetidinyl tryptamines and methods of using such compounds to treat psychiatric disorders. Also provided are pharmaceutical compositions comprising azetidinyl tryptamines.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate, including solvates such as methanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (also referred to as 4-glutarato-N,N-diisopropyltryptamine methanol solvate or 4-glutarato-DiPT·MeOH), and crystalline forms thereof such as crystalline form 1 of 4-glutarato-DiPT·MeOH and ethanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (4-glutarato-N,N-diisopropyltryptamine ethanol solvate or 4-glutarato-N,N-DiPT·EtOH), crystalline 4-glutarato-N,N-DiPT·EtOH, and crystalline forms thereof, including crystalline form 1 of 4-glutarato-N,N-DiPT·EtOH; and to pharmaceutical compositions containing them and to methods of treatment using them. The disclosure further relates to crystalline [3-[2-(methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (baeocystin), such as crystalline form 1 of baeocystin, and to pharmaceutical compositions containing crystalline baeocystin, such as crystalline form 1 of baeocystin, and to methods of treatment using it.

There is disclosed a compound of Formula (I):and any pharmaceutically acceptable salt or zwitterion thereof, wherein: R is hydrogen, methyl or ethyl; R1 is hydrogen or C1-C2 alkoxy; R2 is methyl or a C2-C4 group which may be saturated or unsaturated, branched or linear; and R3, R4, R5 and R6 each are independently selected from hydrogen, hydroxyl, halogen, methyl optionally substituted with hydroxy, methoxy, ethoxy, and a saturated or unsaturated C2-C3 that may be optionally substituted with hydroxyl, with the provisos that: (i) at least two of R4, R5, R6 and R7 must be hydrogen, and (ii) R3, R4, R5 and R6 may be selected such that an adjacent pair thereof join to form a ring having at least 5 members. The compound of Formula (I) is believed useful in treating a disease or disorder in a subject which may be alleviated by a 5HT2A agonist (e.g., CNS disorders and one or more symptoms of any one of depression, alcoholism, tobacco addiction, cocaine addiction, inflammation, cluster headache and PTSD in a subject).

This invention discloses a strain of Maggi-Megaki yeast with amine-reducing and flavor-enhancing capabilities and its applications, belonging to the field of microbial fermentation technology. This invention screened a strain of Maggi-Megaki yeast Y21 from fermented soybean paste, which has the ability to degrade biogenic amines. This strain can completely degrade tryptamine, phenylethylamine, putrescine, cadaverine, spermidine, and spermine; simultaneously, it also has a strong degradation effect on histamine and tyramine, with degradation rates reaching 69.58% and 65.32%, respectively. Using the Maggi-Megaki yeast Y21 described in this invention for inoculation and fermentation can significantly reduce the content of various biogenic amines in fermented soybean paste under low-to-medium salt conditions, especially showing outstanding removal effects on histamine, tyramine, phenylethylamine, and polyamine biogenic amines, increasing the total amount of volatile flavor compounds, and is suitable for the safe production of low-salt fermented foods.

Various aspects of this disclosure relate to the discoveries that (1) acids can catalyze the spontaneous dephosphorylation of phosphoryloxytryptamines into hydroxytryptamines such as psilocybin into psilocin, and (2) hydroxytryptamines are less stable to spontaneous oxidation than phosphoryloxytryptamines. The salt of a phosphoryloxytryptamine and an anion that is the conjugate base of a weak acid can buffer pH upon dissolution of the salt to inhibit the acid-catalyzed dephosphorylation of the phosphoryloxytryptamine and thereby protect it from spontaneous oxidation. Suitable anions include acetate, bicarbonate, dihydrogen phosphate, aspartate, and glutamate.

The invention provides a cross-linked porous polymer for detecting tryptamine and a preparation method and application thereof.The cross-linked porous polymer comprises a BODIPY fluorescent component and a triphenylamine electron withdrawing component and has a pore channel structure, a large specific surface area and an extended pi conjugated system, and the BODIPY fluorescent component and the triphenylamine electron withdrawing component are connected through alkynyl. In the preparation method, the pore size distribution of the material can be regulated and controlled through a reaction solvent, so that the adsorption and enrichment capacity on a target analyte is improved, and meanwhile, the mass transfer and diffusion rate of the analyte in the material is increased. The unique extended pi conjugated skeleton structure can improve the fluorescence signal change amplitude before and after target detection, and the three-dimensional covalent cross-linked network endows the material with excellent chemical / light stability. The fluorescent sensing material organically combines three functions of adsorption enrichment, signal amplification and good stability, and realizes high-sensitivity, rapid and stable detection of tryptamine.

Provided herein are compositions, particularly pharmaceutical compositions, comprising racemic and enantiomerically pure mixtures of tetrahydroharmine (THH), R-tetrahydroharmine ((R)-THH), and S-tetrahydroharmine ((S)-THH), and optionally a tryptamine and / or harmala alkaloid, and pharmaceutically acceptable salts thereof. Also provided are uses of the aforementioned compositions, including medical uses. Also provided are methods of preparing the compositions.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in the treatment of patients suffering from postpartum depression (PPD).

The invention discloses a method for preparing 5-methoxytryptamine by a one-pot method, which comprises the following steps: by taking 1, 2, 3, 4-tetrahydro-6-methoxy-1-oxo-beta-carboline as a raw material, neutralizing by using strong acid instead of traditional acetic acid during ring-opening reaction, and carrying out decarboxylation reaction on a ring-opening product without separating to prepare the 5-methoxytryptamine. The method can completely avoid the generation of sodium acetate in the ring-opening reaction in the traditional technology, reduces the influence on the next decarboxylation reaction, and can directly perform the decarboxylation reaction without separating the ring-opening product, thereby effectively solving the problem that the decarboxylation reaction needs to be directly performed in the prior art. According to the method for preparing the 5-methoxytryptamine by using the 2, 3, 4-tetrahydro-6-methoxy-1-oxo-beta-carboline as the raw material, the defects that weak acid is left and an intermediate needs to be separated in the method are overcome, and the reaction route is shortened. The method improves the product yield and purity, has the advantages of simplicity and convenience in operation, high product purity, less three wastes and low cost, and is suitable for large-scale industrial production.

The invention discloses a tryptanthrin derivative and a preparation method and application thereof, the invention provides a series of novel tryptanthrin derivatives, the prepared tryptanthrin derivatives have a good dual-inhibition effect on IDO1 / TDO enzyme, the compound prepared by the invention is 2-2, the inhibition activity of the compound on IDO1 reaches the same level of IDO1 positive drug Epacadstat, and the tryptanthrin derivatives can be used for preparing a medicine for treating IDO1. The TDO inhibitory activity obviously exceeds the level of a TDO positive drug LM10, and the IDO1 / TDO dual inhibitory activity is considered at the same time. The compound has a wide application prospect in the field of preparation of drugs for preventing or treating IDO1 / TDO-mediated related diseases.

The application belongs to the field of synthesis of pharmaceutical intermediates and discloses a lactam hydrolase mutant, a decarboxylase mutant and application of the lactam hydrolase mutant and the decarboxylase mutant in preparation of 5-methoxytryptamine. The lactam hydrolase mutant and the decarboxylase mutant with high activity are obtained by mutating specific positions of the lactam hydrolase and the decarboxylase. When the lactam hydrolase mutant and the decarboxylase mutant are used in preparation of 5-methoxytryptamine, the conversion rate and the yield are improved, the conditions are mild, and the use of acid and alkali reagents is reduced.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a psychiatric or nervous system disorder in mothers of children 18 months of age or younger, wherein the 5-MeO-DMT or the pharmaceutically acceptable salt thereof is administered via an intravenous, intramuscular, or subcutaneous route.